Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Fujifilm to Introduce Automatic Aseptic Filling System in US Bio CDMO Hub
January 16, 2019
- Mitsubishi Tanabe Stepping Up Rupafin Promotion in November: Anterio
January 15, 2019
- Japan Pharma Market Sags 2% in April-December as Pricing Overhaul Weighs: Encise
January 15, 2019
- Avastin Top-Seller Medicine in Japan in December: Encise Snapshot
January 11, 2019
- Wakamoto Kicks Off Japan PIII for Glaucoma Drug
January 11, 2019
- Latuda Succeeds in PIII Schizophrenia Study, Japan NDA Submission Planned by September
January 11, 2019
- Fujifilm’s Next-Generation Technology Doubles Antibody Productivity, Reduces Production Time by 30%
January 11, 2019
- NanoCarrier Submits CTA in EU for PII Study of NC-6004-Keytruda Combo for Head and Neck Cancer
January 11, 2019
- Daiichi Sankyo, Tokyo Institute of Technology Launch Open Innovation Research for Type 1 Diabetes Treatment Using iPS Cells
January 11, 2019
- Opdivo Extends OS in Second-Line Esophageal Cancer
January 10, 2019
- Chugai Completes Transfer of 13 Off-Patent Brands to Taiyo
January 10, 2019
- Kowa, Nissan Chemical Win US Patent Case over Livalo Crystal Form
January 10, 2019
- Meiji to Set Up JV with Canadian Firm to Develop Novel β-lactamase Inhibitor
January 9, 2019
- Eisai Recalls Azeptin after It Fails Dissolution Tests
January 9, 2019
- Investigator-Initiated US PII Study to Start for Telomelysin/Keytruda Combo: Oncolys
January 9, 2019
- Kyorin Introduces Voluntarily Recall of Desalex
January 9, 2019
- Fycompa Designated for Priority Review in China
January 9, 2019
- Takeda Completes £46 Billion Shire Acquisition
January 8, 2019
- Kyowa Kirin Files Burosumab in Japan
January 8, 2019
- Takeda Revving Up Collaboration Efforts on I/O Front
January 8, 2019
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…